Apalutamide-induced ichthyosiform eruption
https://doi.org/10.4081/dr.2023.9734
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Not available
Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503. DOI: https://doi.org/10.1158/0008-5472.CAN-11-3948
Chi KN, Agarwal N, Bjartell A et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13-24. DOI: https://doi.org/10.1056/NEJMoa1903307
Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021;79(1):150-158. DOI: https://doi.org/10.1016/j.eururo.2020.08.011
Uemura H, Koroki Y, Iwaki Y et al. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020;20(1):139. DOI: https://doi.org/10.1186/s12894-020-00689-0
Miyagawa F, Akioka N, Yoshida N et al. Psoriatic Skin Lesions after Apalutamide Treatment. Acta Derm Venereol. 2022;102:adv00659. DOI: https://doi.org/10.2340/actadv.v102.858
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
